BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 30230774)

  • 1. [Negative symptoms in schizophrenia - overview and practical implications].
    Klaus F; Dorsaz O; Kaiser S
    Rev Med Suisse; 2018 Sep; 14(619):1660-1664. PubMed ID: 30230774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Negative Symptoms in Schizophrenia - an Overview].
    Klaus F; Kaiser S; Kirschner M
    Ther Umsch; 2018 Jun; 75(1):51-56. PubMed ID: 29909762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recognizing primary vs secondary negative symptoms and apathy vs expression domains.
    Kirkpatrick B
    J Clin Psychiatry; 2014 Apr; 75(4):e09. PubMed ID: 24813410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individual negative symptoms and domains - Relevance for assessment, pathomechanisms and treatment.
    Kaiser S; Lyne J; Agartz I; Clarke M; Mørch-Johnsen L; Faerden A
    Schizophr Res; 2017 Aug; 186():39-45. PubMed ID: 27453425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing concepts in negative symptoms: primary vs secondary and apathy vs expression.
    Kirkpatrick B
    J Clin Psychiatry; 2014; 75 Suppl 1():3-7. PubMed ID: 24581452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathophysiology of negative symptom dimensions of schizophrenia - Current developments and implications for treatment.
    Bègue I; Kaiser S; Kirschner M
    Neurosci Biobehav Rev; 2020 Sep; 116():74-88. PubMed ID: 32533996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurophysiological correlates of Avolition-apathy in schizophrenia: A resting-EEG microstates study.
    Giordano GM; Koenig T; Mucci A; Vignapiano A; Amodio A; Di Lorenzo G; Siracusano A; Bellomo A; Altamura M; Monteleone P; Pompili M; Galderisi S; Maj M;
    Neuroimage Clin; 2018; 20():627-636. PubMed ID: 30202724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A transnosographic approach of negative symptoms pathophysiology in schizophrenia and depressive disorders.
    Guessoum SB; Le Strat Y; Dubertret C; Mallet J
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Apr; 99():109862. PubMed ID: 31927053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Covariation between motor signs and negative symptoms in drug-naive subjects with schizophrenia-spectrum disorders before and after antipsychotic treatment.
    Peralta V; de Jalón EG; Campos MS; Cuesta MJ
    Schizophr Res; 2018 Oct; 200():85-91. PubMed ID: 28864283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The clinic of apathy in schizophrenia: a critical review of the issue].
    Yazbek H; Raffard S; Del-Monte J; Pupier F; Larue A; Boulenger JP; Gély-Nargeot MC; Capdevielle D
    Encephale; 2014 Jun; 40(3):231-9. PubMed ID: 23958346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans.
    Neill JC; Harte MK; Haddad PM; Lydall ES; Dwyer DM
    Eur Neuropsychopharmacol; 2014 May; 24(5):822-35. PubMed ID: 24287012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive Emotions Program for Schizophrenia (PEPS): a pilot intervention to reduce anhedonia and apathy.
    Favrod J; Nguyen A; Fankhauser C; Ismailaj A; Hasler JD; Ringuet A; Rexhaj S; Bonsack C
    BMC Psychiatry; 2015 Sep; 15():231. PubMed ID: 26419356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two Factors, Five Factors, or Both? External Validation Studies of Negative Symptom Dimensions in Schizophrenia.
    Ahmed AO; Kirkpatrick B; Granholm E; Rowland LM; Barker PB; Gold JM; Buchanan RW; Outram T; Bernardo M; Paz García-Portilla M; Mane A; Fernandez-Egea E; Strauss GP
    Schizophr Bull; 2022 May; 48(3):620-630. PubMed ID: 35020936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [History and current state of the problem of negative disorders (research of nosological period)].
    Smulevich AB; Lobanova VM; Voronova EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(2):122-130. PubMed ID: 33728861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary negative symptoms - A review of mechanisms, assessment and treatment.
    Kirschner M; Aleman A; Kaiser S
    Schizophr Res; 2017 Aug; 186():29-38. PubMed ID: 27230288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Negative symptoms of schizophrenia and compliance with medication.
    Tattan TM; Creed FH
    Schizophr Bull; 2001; 27(1):149-55. PubMed ID: 11215543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of primary negative symptoms on functional outcomes in schizophrenia.
    Fervaha G; Foussias G; Agid O; Remington G
    Eur Psychiatry; 2014 Sep; 29(7):449-55. PubMed ID: 24630742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Negative symptoms in schizophrenia: psychotherapeutic approaches].
    Azorin JM; Adida M; Belzeaux R; Pringuey D; Micoulaud Franchi JA; Simon N; Cermolacce M; Kaladjian A; Fakra E
    Encephale; 2015 Dec; 41(6 Suppl 1):6S57-60. PubMed ID: 26776394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A critical study of the influence of negative symptoms on the therapeutic response in schizophrenia].
    Acuña MJ; Martín J; Noval D; Blanco M
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1998; 26(4):209-13. PubMed ID: 9807853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Pleasure and Motivation in Schizophrenia: A Randomized Controlled Clinical Trial.
    Favrod J; Nguyen A; Chaix J; Pellet J; Frobert L; Fankhauser C; Ismailaj A; Brana A; Tamic G; Suter C; Rexhaj S; Golay P; Bonsack C
    Psychother Psychosom; 2019; 88(2):84-95. PubMed ID: 30783071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.